Studies comparing the leading follicle diameter in natural  cycles with CC cycles found that CC cycles have significantly larger leading  follicles, measuring between 18 and 30 mm. Because of this wide range, many  investigators did not consider this parameter to be a prognostic indicator for  IUI success.
    During the last decade, the use of aromatase inhibitors for  ovulation induction has rapidly expanded. Studies have shown the efficacy of  aromatase inhibitors in ovulation induction in patients who have a poor  response to CC, in patients with polycystic ovary syndrome who are resistant to  CC, and in patients with unexplained infertility.
    Authors Palatnik et al investigated the optimal size of the  leading follicle before hCG administration in cycles with CC and letrozole.  Secondarily, examined whether there is a difference in the optimal leading  follicle size between cycles with CC and letrozole.
    This retrospective analysis included women undergoing  ovulation induction followed by IUI at an academic reproductive medicine center  from 2004 to 2009. The study group included all women undergoing a first cycle  of IUI in our center after treatment with either CC or letrozole in which a  midcycle ultrasound was performed and ovulation was triggered with hCG.
    The women in their first ovulation induction/IUI cycle  underwent transvaginal ultrasound monitoring between cycle days 11 and 13 after  receiving 5 days of treatment with 100 mg of CC daily or 5 mg of letrozole  daily starting on days 3 to 5. At the time of the ultrasound, the mean diameter  of the follicle was calculated from measurements in two perpendicular planes  for any follicles measuring greater than 14 mm. If at least one follicle ≥18  mm in mean diameter was detected, hCG was administered the same morning, and  IUI was scheduled 24 hours later.
    Patients were instructed to obtain a quantitative serum hCG  measurement 14 days after the insemination if they did not menstruate. If the  result was positive, the patient was scheduled for a transvaginal ultrasound 6  to 7 weeks after the last menstrual period to document the pregnancy location  and fetal heart activity. Main Outcome included Leading follicle diameter and intrauterine  insemination outcome.
    Eight percent of patients were excluded because their  leading follicle was less than 18 mm by days 11 to 13. Pregnancy was recorded  as clinical pregnancy with fetal heart activity seen at 6- to 7-week  transvaginal ultrasound. 
    For both CC and letrozole, higher pregnancy rates were  achieved when the leading follicles were in the 23 to 28 mm range. The  optimal size of the leading follicle was not statistically significantly  different between cycles using CC or letrozole. However, for  each endometrial thickness, the optimal follicular size of the leading follicle  was different. 
    Each additional millimeter of endometrial thickness  increased the optimal follicular size by 0.5 mm. Thicker endometrial lining led to  a higher probability of pregnancy.
    In this study, authors examined the optimal follicular size  before hCG administration to yield the highest pregnancy rates in IUI cycles  stimulated using CC or letrozole.
    In this study, the important factors for clinical pregnancy  after IUI were found to be maternal age, primary infertility diagnosis,  endometrial thickness, the size of the leading follicle, and the drug type.  Sperm motility and the presence of other mature follicles were not found to be  statistically significantly correlated with pregnancy. One possible explanation  for the sperm motility not being a predictive factor of the cycle outcome may  be because the majority of men in our couples had total motile sperm count  values above the threshold.
    In this study, authorz found that there is an optimal size  for the leading follicle that maximizes the probability of pregnancy, with  lower rates for both smaller and larger leading follicles. This optimal size is  influenced by the endometrial thickness. For both drugs, higher pregnancy rates  were achieved with the leading follicle being in the range of 23 to 28 mm.  Within that range, pregnancy rates were higher when the larger follicles were  accompanied by a thicker endometrium and vice versa. These findings can be seen  as a similar response of the endometrium and the follicles to the  ovulation-induction agent, letrozole or CC: an appropriate response affected  both the follicles and the endometrium in the same way. Possibly, this reflects  coordination between follicular growth and the endometrial lining. 
    Larger follicles would be expected to produce higher levels  of estradiol that would then stimulate the endometrial lining more, and smaller  follicles would produce lower levels of estradiol and thus produce a thinner  lining. When this coordination is disrupted, lower pregnancy levels are the  result. The size of the leading follicle that resulted in a pregnancy was not  statistically significantly different in cycles with CC and letrozole. However,  it  appears that cycles stimulated with CC had a wider range of follicle sizes,  which resulted in similar rates of pregnancy as compared with letrozole.
    Endometrial lining was found to be a predictive factor of  achieving pregnancy, and thicker endometrial lining resulted in higher  pregnancy rates when the leading follicle size was close to the optimum  (P=.002).
    The authors concluded, "Our study has shown that the optimal  size of the leading follicle in ovulation induction with CC and letrozole is  similar for both drugs and is closely related to the endometrial thickness of  the cycle. Keeping that relationship in mind can help in planning the IUI cycle  and in timing the hCG administration."
    Source: Anna  Palatnik, Estil Strawn, Aniko Szabo and Paul Robb, Fertility and Sterility
    doi:10.1016/j.fertnstert.2012.02.018
     
 
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.